Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269993 | 1.00 | PDE2A (0.42) | PDE2A | |
| SCHEMBL13853072 | 0.79 | PDE2A (0.37) | PDE2A | |
| SCHEMBL27781355 | 0.79 | PDE2A (0.37) | PDE2A | |
| SCHEMBL19788572 | 0.77 | PNMT (0.39) | PDE2A | |
| SCHEMBL247015 | 0.77 | PDE2A (0.34) | PDE2A | |
| SCHEMBL22476053 | 0.77 | PNMT (0.39) | PDE2A | |
| SCHEMBL4174119 | 0.77 | PDE2A (0.34) | PDE2A | |
| SCHEMBL28310884 | 0.70 | PDE2A (0.53) | PDE2A | |
| SCHEMBL12970079 | 0.69 | MBNL1 (0.40) | — | |
| SCHEMBL252535 | 0.68 | MAPT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PDE2A 2979/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PDE2A 2979/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PDE2A 2979/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PDE2A 2979/4885 |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PDE2A 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.